Regenerative medicine company Orthocell Limited has announced it has expanded its presence in Asia with the first patients treated with its world-leading tendon repair therapy in Hong Kong.
The two patients underwent the Ortho-ATITM therapy last Friday, performed by respected Hong Kong Orthopaedic Surgeon Jason Brockwell from leading sports orthopaedic group Asia Medical Specialists.
The patients are receiving therapy to treat degenerate hamstring tendons that have been resistant to conservative treatment options such as corticosteroid injections and exercise regimes.
“This is an important step forward in the expansion of the Ortho-ATITMtreatment into Asia and comes on the back of solid clinical data that has been published and presented over the past year,” Orthocell Managing Director Paul Anderson said.
“There is great interest for a clinically effective treatment that has long term durability and cost effectiveness.”
Ortho-ATITM involves taking tendon cells from a patient, expanding their number in an Australian Therapeutic Goods Authority-licensed laboratory and then injecting them into the patient’s damaged tendon to address the underlying pathology and regenerate the damaged tissue.
Asia is a key growth region for Orthocell and its innovative regenerative medicine therapies. The global regenerative medicine market has been forecast to reach $US67.6 billion in 2020, from $US16.4 billion in 2014, with the Asia-Pacific region expected to be the fastest growing region.
